Shield Therapeutics

Edison Investment Research is terminating coverage on Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Thematics

Latest

UK equities: A generational opportunity?

Renewable energy developers – Creating value for investors

Healthcare-focused trusts: A sector on the mend

Audiovisual

Latest

Oryzon Genomics – executive interview

Basilea Pharmaceutica – executive interview

Webinar – AI for IR: About our coaching programme

About Edison

About Edison

Careers

Shield Therapeutics (AIM: STX)

Latest Insights

Shield Therapeutics — New CFO to support US traction

Shield Therapeutics — Delivering what the doctor ordered

Shield Therapeutics — Ramped up and heading into a stronger H223

Shield Therapeutics — FY23 a key year for business traction

Sector

Shield Therapeutics — 2021 all eyes on Accrufer US launch

Shield Therapeutics — Accrufer coming to America

Shield Therapeutics — Beefing up for the US opportunity

Shield Therapeutics — Close but no cigar

Shield Therapeutics — US partner next major inflection point

Shield Therapeutics — AEGIS-H2H update – non-inferiority at 24 weeks

Shield Therapeutics — All eyes on a US partnering deal

Shield Therapeutics — Next step a US partnering deal

Shield Therapeutics — Tim Watts succeeds Carl Sterritt as CEO

Shield Therapeutics — AEGIS-2 update

Shield Therapeutics — 2019 a landmark year

Shield Therapeutics — Feraccru out-licensed in China

Shield Therapeutics — The land of opportunity awaits Accrufer

Shield Therapeutics — FDA approval attained, sales execution now key

Bitesize briefing – Shield Therapeutics

Shield Therapeutics — Next step US Feraccru approval

Executive interview – Shield Therapeutics

Shield Therapeutics — Feraccru performs again in a Phase III study

Shield Therapeutics — Fortified for growth